Associations between childhood maltreatment and inflammatory markers
Alish B. Palmos,
Stuart Watson,
Tom Hughes,
Andreas Finkelmeyer,
R. Hamish McAllister-Williams,
Nicol Ferrier,
Ian M. Anderson,
Rajesh Nair,
Allan H. Young,
Rebecca Strawbridge,
Anthony J. Cleare,
Raymond Chung,
Souci Frissa,
Laura Goodwin,
Matthew Hotopf,
Stephani L. Hatch,
Hong Wang,
David A. Collier,
Sandrine Thuret,
Gerome Breen,
Timothy R. Powell
Affiliations
Alish B. Palmos
King's College London, Social, Genetic and Developmental Psychiatry Centre, UK
Stuart Watson
Academic Clinical Senior Lecturer, Institute of Neuroscience, Wolfson Research Centre, Newcastle University, Campus for Ageing and Vitality; and Northumberland Tyne and Wear NHS Foundation Trust, UK
Tom Hughes
Associate Medical Director for Research, Leeds and York NHS Partnership Foundation Trust, UK
Andreas Finkelmeyer
Research Associate, Institute of Neuroscience, Wolfson Research Centre, Newcastle University, Campus for Ageing and Vitality, UK
R. Hamish McAllister-Williams
Professor of Affective Disorders, Institute of Neuroscience, Wolfson Research Centre, Newcastle University, Campus for Ageing and Vitality; and Northumberland Tyne and Wear NHS Foundation Trust, UK
Nicol Ferrier
Emeritus Professor, Institute of Neuroscience, Wolfson Research Centre, Newcastle University, Campus for Ageing and Vitality; and Northumberland Tyne and Wear NHS Foundation Trust, UK
Ian M. Anderson
Honorary Professor of Psychiatry, Neuroscience and Psychiatry Unit, Manchester University and Manchester Academic Health Science Centre, UK
Rajesh Nair
Associate Clinical Researcher, Consultant Psychiatrist, Institute of Neuroscience, Wolfson Research Centre, Newcastle University, Campus for Ageing and Vitality; and Northumberland Tyne and Wear NHS Foundation Trust, UK
Professor of Mood Disorders, King's College London, Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, South London and Maudsley NHS Foundation Trust; and National Institute for Health Research Biomedical Research Centre for Mental Health, Institute of Psychiatry, Psychology and Neuroscience,the Maudsley Hospital and King's College London, UK
Postdoctoral Research Associate, King's College London, Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience; and National Institute for Health Research Biomedical Research Centre for Mental Health, Institute of Psychiatry, Psychology and Neuroscience, the Maudsley Hospital and King's College London, UK
Anthony J. Cleare
Professor of Psychopharmacology and Affective Disorders, King's College London, Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, South London and Maudsley NHS Foundation Trust; and National Institute for Health Research Biomedical Research Centre for Mental Health, Institute of Psychiatry, Psychology and Neuroscience, the Maudsley Hospital and King's College London, UK
Raymond Chung
Research Assistant, King's College London, Social, Genetic and Developmental Psychiatry Centre; and National Institute for Health Research Biomedical Research Centre for Mental Health, Institute of Psychiatry, Psychology and Neuroscience, the Maudsley Hospital and King's College London, UK
Souci Frissa
King’s NIHR Global Health Unit Coordinator, Health Services and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London,UK
Laura Goodwin
Visiting Lecturer, Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience,King's College London; and Lecturer in Epidemiology, Department of Psychological Sciences, University of Liverpool, UK
Matthew Hotopf
Professor of General Hospital Psychiatry, Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London,South London and Maudsley NHS Foundation Trust; and National Institute for Health Research Biomedical Research Centre for Mental Health, Institute of Psychiatry, Psychology and Neuroscience, the Maudsley Hospital and King's College London, UK
Stephani L. Hatch
Reader in Sociology and Epidemiology, King's College London, Health Services and Population Research, Institute of Psychiatry, Psychology and Neuroscience, UK
Hong Wang
Senior Research Scientist, Eli Lilly and Company, Lilly Corporate Center, USA
David A. Collier
Research Fellow, Eli Lilly and Company, UK
Sandrine Thuret
Reader in Neuroscience and Mental Health, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London,UK
Gerome Breen
Reader of Neuropsychiatric and Translational Genetics, Social, Genetic and Developmental Psychiatry Centre, King's College London; and National Institute for Health Research Biomedical Research Centre for Mental Health, Institute of Psychiatry, Psychology and Neuroscience,the Maudsley Hospital and King's College London, UK
BackgroundChildhood maltreatment is one of the strongest predictors of adulthood depression and alterations to circulating levels of inflammatory markers is one putative mechanism mediating risk or resilience.AimsTo determine the effects of childhood maltreatment on circulating levels of 41 inflammatory markers in healthy individuals and those with a major depressive disorder (MDD) diagnosis.MethodWe investigated the association of childhood maltreatment with levels of 41 inflammatory markers in two groups, 164 patients with MDD and 301 controls, using multiplex electrochemiluminescence methods applied to blood serum.ResultsChildhood maltreatment was not associated with altered inflammatory markers in either group after multiple testing correction. Body mass index (BMI) exerted strong effects on interleukin-6 and C-reactive protein levels in those with MDD.ConclusionsChildhood maltreatment did not exert effects on inflammatory marker levels in either the participants with MDD or the control group in our study. Our results instead highlight the more pertinent influence of BMI.Declaration of interestD.A.C. and H.W. work for Eli Lilly Inc. R.N. has received speaker fees from Sunovion, Jansen and Lundbeck. G.B. has received consultancy fees and funding from Eli Lilly. R.H.M.-W. has received consultancy fees or has a financial relationship with AstraZeneca, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Ferrer, Janssen-Cilag, Lundbeck, MyTomorrows, Otsuka, Pfizer, Pulse, Roche, Servier, SPIMACO and Sunovian. I.M.A. has received consultancy fees or has a financial relationship with Alkermes, Lundbeck, Lundbeck/Otsuka, and Servier. S.W. has sat on an advisory board for Sunovion, Allergan and has received speaker fees from Astra Zeneca. A.H.Y. has received honoraria for speaking from Astra Zeneca, Lundbeck, Eli Lilly, Sunovion; honoraria for consulting from Allergan, Livanova and Lundbeck, Sunovion, Janssen; and research grant support from Janssen. A.J.C. has received honoraria for speaking from Astra Zeneca, honoraria for consulting with Allergan, Livanova and Lundbeck and research grant support from Lundbeck.
